Sarcoidosis
Sarcoidosis is a complex multi-system inflammatory disease, elusive in origin, formidable in manifestations, and heterogeneous in its course. Our company has a robust team of dedicated professionals who harness advanced technology, which supports your research of developing innovative, targeted therapies.
Introduction to Sarcoidosis
Sarcoidosis is a systemic disease of unknown etiology characterized by the formation of noncaseating granulomas. It commonly affects the lungs, lymph nodes, eyes, and skin, subsequently leading to organ damage and depreciation in the quality of life. its presence is felt worldwide with an overall prevalence rate of approximately 2.3 to 11 per 100,000 population.
Fig.1 Current and investigational therapeutics for sarcoidosis based on pathogenesis. (Gerke A. K., 2020)Pathogenesis of Sarcoidosis
The pathogenesis of sarcoidosis is that the immune system makes an excessive immune response to unknown substances or triggers, resulting in the formation of immune cell clusters. Sarcoidosis granulomas are curiously intricate structures formed by unique aggregates of multinucleated giant cells and epithelioid macrophages. This abnormal immune response can cause inflammation and destroy the normal function of the affected organs.
Biomarkers for Sarcoidosis Diagnostics
The cutting-edge technological tools such as transcriptomics to identify important 'molecular maps' in sarcoidosis are conducive to identifying useful biomarkers for the accurate diagnosis and development of personalized therapeutic. There are some biomarkers associated with sarcoidosis.
- Serum Angiotensin-Converting Enzyme
- Lysozyme
- Neopterin
- YKL40
- sCD163
- CC Chemokine Ligand 18
- Serum Amyloid A
- Chitotriosidase
Therapeutics of Sarcoidosis
Small Molecule Drugs Therapy
Immunosuppressive agents, including methotrexate or azathioprine, are used in individuals who either do not respond to or can't tolerate steroids. Antimalarial agents such as chloroquine and hydroxychloroquine have shown efficacy in treating cutaneous manifestations of sarcoidosis.
Monoclonal Antibodies Therapy
Newer therapies like monoclonal antibodies against TNF itself (infliximab, adalimumab, and golimumab) and targeted B cell therapy (rituximab) have emerged as promising frontiers in improving individuals' quality of life.
Our Services
As a frontier in the battle against rare diseases, our company is dedicated to lending scientific vigor to the study of sarcoidosis. We can provide services from mechanism research to new therapy evaluation, including animal models and innovative therapeutic platform development to support your research of sarcoidosis.
Platforms of Sarcoidosis Therapy Development
Animal Models of Sarcoidosis
The animal models caused by chemical inducting or genetic engineering can help you provide insights into the pathogenesis of sarcoidosis and propel innovative therapy creation.
| Chemical-induced Models | ||
|---|---|---|
| Chemical-induced models cause the formation of granulomas using Th1-type immune response inducing Mycobacteria-specific antigens such as superoxide dismutase A (SodA), early secreted antigenic target 6-kD protein (ESAT-6), and catalase-peroxidase (KatG). Additionally, injecting an animal with P.acnes or multi-walled carbon nanotube (MWCNT) can encourage granuloma formation. | ||
| Optional Models |
|
|
|
|
|
|
||
| Genetically Engineered Models | ||
| Gene editing techniques such as CRISPR/Cas9 allow modifying animal-specific genes like tuberous sclerosis complex 2 (Tsc2) genes, enabling these animals to exhibit systemic granuloma characteristics (on the lung, lymph nodes, liver, and skin). | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Zebrafish, Rabbit, Non-Human Primates, Others | |
Our company can offer all-encompassing services for sarcoidosis to support your pharmacokinetics analysis and drug safety evaluation. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Gerke, Alicia K. "Treatment of Sarcoidosis: A Multidisciplinary Approach." Frontiers in immunology 11 (2020): 545413.
- Kraaijvanger, Raisa et al. "Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects." Frontiers in immunology 11 (2020): 1443.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.